iCAD (NASDAQ:ICAD) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of iCAD, Inc. (NASDAQ:ICAD) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Price Performance

The stock has a market cap of $50.43 million, a price-to-earnings ratio of -14.62 and a beta of 1.40. The business’s 50 day moving average is $1.83 and its 200 day moving average is $1.61.

Institutional Investors Weigh In On iCAD

A hedge fund recently bought a new stake in iCAD stock. Essex LLC acquired a new position in shares of iCAD, Inc. (NASDAQ:ICAD) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned about 0.52% of iCAD at the end of the most recent quarter. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.